Effect of non-pharmaceutical interventions on the incidence of respiratory viruses at a tertiary cancer care center.

Authors:
Clark B; Cintron M; Kamboj M; Babady NE.

Journal:
J Clin Virol

Publication Year: 2023

DOI:
10.1016/j.jcv.2023.105442

PMCID:
PMC10066859

PMID:
37075690

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Clin Virol

Abbreviation: J Clin Virol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Virology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Clinical utility of SARS-CoV-2 subgenomic RT-PCR in a pediatric quaternary care setting.
Osborn LJ; Chen PY; Flores-Vazquez J and 6 more (2023) - Transparency Score: 3/6
Correlation between monkeypox viral load and infectious virus in clinical specimens.
Lim CK; McKenzie C; Deerain J and 6 more (2023) - Transparency Score: 3/6
Evaluation of a multiplexed oligonucleotide ligation assay for SARS-CoV-2 variant identification.
Solis D; Sibai M; Kung F and 8 more (2023) - Transparency Score: 2/6
Evaluation of four laboratory-based high-throughput SARS-CoV-2 automated antigen tests compared to …
Leineweber TD; Ghathian K; Lisby JG and 15 more (2023) - Transparency Score: 4/6
Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, s…
Ambrosch A; Luber D; Klawonn F and 1 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of Competing Interest None"

Evidence found in paper:

"Funding This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025